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Abstract
Aims: The aim of the study was to evaluate the prognostic utility of right heart catheterisation (RHC)-
derived measures among patients undergoing transcatheter aortic valve implantation (TAVI).
Methods and results: Data of 469 patients included in the Bern TAVI Registry between August 2007 
and December 2012 and undergoing preoperative RHC were analysed. The relationship between haemo-
dynamic parameters and survival was evaluated with Cox proportional hazards models. At two-year fol-
low-up, 118 patients had died (25.1%). At multivariable analysis, diabetes (hazard ratio [HR] 1.95, 95% 
confidence interval [CI]: 1.28-2.96, p=0.001), transapical access (HR 1.66, 95% CI: 1.07-2.56, p=0.02), and 
moderate or severe mitral regurgitation (HR 1.55, 95% CI: 1.00-2.39, p=0.04) were independent predictors 
of two-year mortality, whereas no correlation between RHC-derived measures and mortality was found. 
Furthermore, the addition of haemodynamic variables did not significantly improve the prognostic power of 
a model incorporating clinical and echocardiographic data (Harrell’s C-index: 0.667, 95% CI: 0.615-0.719 
vs. 0.662, 95% CI: 0.612-0.713, p=0.47).
Conclusions: On the basis of a comprehensive clinical and echocardiographic evaluation, RHC performed 
prior to TAVI does not add incremental prognostic value.
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Abbreviations
AS aortic stenosis
AUC area under the curve
CI confidence interval
HR hazard ratio
LVEF left ventricular ejection fraction
NYHA New York Heart Association
PAP pulmonary artery pressure
PARTNER Placement of Aortic Transcatheter Valves
RAP right atrial pressure
RHC right heart catheterisation
SD standard deviation
STS Society of Thoracic Surgeons
TAVI transcatheter aortic valve implantation
Introduction
Haemodynamic parameters measured at right heart catheterisa-
tion (RHC), such as mean right atrial pressure and pulmonary 
arterial compliance, have proved to be reliable predictors of out-
comes in several clinical settings including pulmonary arterial 
hypertension and chronic heart failure1,2. Severe aortic valve ste-
nosis (AS) produces significant changes in the interdependent left 
and right ventricular haemodynamics3. Indeed, sustained pres-
sure overload induces the development of myocardial hypertro-
phy which progressively impairs the diastolic properties of the 
left ventricle; its heightened filling pressures are then passively 
transmitted backwards, eliciting a reactive component within the 
pulmonary vasculature4. Multiple lines of evidence support the 
negative impact of baseline pulmonary hypertension on clinical 
outcomes after transcatheter aortic valve implantation (TAVI)5-7. 
However, so far, a systematic appraisal of the predictive value of 
other RHC-derived parameters in this context is lacking. Our aim 
was to identify, among haemodynamic indices obtained at RHC, 
the determinants of mortality at two years after TAVI and to assess 
whether preoperative RHC could improve the risk stratification of 
patients undergoing TAVI.
Methods
STUDY POPULATION AND ENDPOINT
We analysed data of patients undergoing RHC prior to TAVI 
who were consecutively included in the Bern TAVI Registry 
between August 2007 and December 2012. TAVI was performed 
on the basis of a multidisciplinary consensus and as previously 
described8. Active follow-up was planned at 30 days, one and 
two years by in-hospital visits or phone interview. All poten-
tial adverse events were adjudicated by a dedicated clinical 
events committee according to the standardised endpoint defi-
nitions proposed by the Valve Academic Research Consortium. 
The study adheres to the ethical principles of the Declaration of 
Helsinki. The Registry was approved by the local ethics commit-
tee, and written informed consent was mandatory for patients to 
participate. The primary study endpoint was all-cause mortality 
at two years.
RIGHT HEART CATHETERISATION
RHC was performed at the time of preprocedural coronary angio-
graphy, as part of a standardised institutional protocol for the com-
prehensive assessment of the severity of the AS and the global 
patient haemodynamic profile. Briefly, fluid-filled catheters con-
nected to pressure transducers were used to record pressures. After 
review of haemodynamic traces, the following parameters were 
collected: mean right atrial pressures (mean RAP), systolic and 
end-diastolic pressures of the right and left ventricle and systolic, 
diastolic and mean pulmonary artery pressures (PAP). Cardiac out-
put was computed with the modified Fick method and indexed to 
body surface area to obtain the cardiac index.
STATISTICAL ANALYSIS
Normally distributed variables were expressed as mean±standard 
deviation (SD), categorical variables as number and percentages. 
Multiple imputation of missing values using chained equations was 
used throughout to account for, and impute, missing data in predictor 
variables (20 data sets created), and Rubin’s rule was used to combine 
the results of the data sets in all predictor analyses. Cox proportional 
hazards models using univariate analysis were used to test the asso-
ciation between predictor variables and mortality at two years after 
TAVI. Considering the large number of continuous predictor vari-
ables, each was additionally evaluated for potential non-linear effects 
(e.g., curvilinear or quadratic effects), but none was found. Estimates 
of hazard ratios (HR) and 95% confidence intervals (CI) are pro-
vided. To investigate the prognostic contribution of RHC-derived 
parameters to clinical and echocardiographic findings at baseline, 
a stepwise procedure was used. Harrell’s C-index and the area under 
the curve (AUC) for clinical predictor variables (age, body mass 
index, diabetes, previous cerebrovascular accident, chronic obstruc-
tive pulmonary disease, transapical access and STS score) were first 
determined (clinical model). Subsequently, we added the echocardio-
graphic predictor variables (moderate or severe mitral regurgitation, 
left ventricular ejection fraction and mean aortic valve gradient) to 
the clinical model (clinical with echo model). Variable selection of 
these two models was based on previously published literature tag-
ging these variables as relevant for mortality or risk assessment of 
TAVI patients, and therefore they were used irrespective of the effect 
on mortality in our patient population. Finally, the RHC-derived 
predictor variables were added singly, of which pulmonary arterial 
compliance and mean RAP were retained. Variable selection of the 
RHC-derived predictor variables was based on single inclusion into 
the clinical with echo model, and RHC-derived predictor variables 
were retained showing a p<0.3 effect on mortality. The prognostic 
contribution of RHC was determined by comparison of AUC calcu-
lated at each step. All analyses were performed using Stata Statistical 
Software, Release 14 (StataCorp LP, College Station, TX, USA), and 
statistical significance was defined as p<0.05.
Results
Of 606 patients included in the Bern TAVI Registry, 469 (77.3%) 
underwent RHC prior to TAVI. The majority of TAVI procedures 
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were performed through the transfemoral access (80%); 18% of 
cases were transapical and 1% trans-subclavian. At two years, 
118 patients (25.1%) had died and clinical follow-up was avail-
able in 346 of 351 patients (98.5%) still alive. Clinical, echocardio-
graphic, and procedural characteristics were similar between patients 
who underwent RHC and those who did not (data not shown).
BASELINE CLINICAL AND ECHOCARDIOGRAPHIC 
CHARACTERISTICS
Table 1 shows the baseline clinical features of the entire popula-
tion and of patients dead or alive at two-year follow-up. Compared 
to patients alive at two years after TAVI, patients who had died 
were found to have higher rates of diabetes mellitus (39% vs. 25%, 
HR 1.74, 95% CI: 1.20-2.52, p=0.003), atrial fibrillation (71% vs. 
68%, HR 1.46, 95% CI: 1.01-2.11, p=0.04), and a greater opera-
tive risk (logistic EuroSCORE: 27.6±15.5 vs. 22.4±13.1, HR 1.02, 
95% CI: 1.01-1.03, p<0.001 and STS score: 8.4±5.4 vs. 6.4±4.1, 
HR 1.06, 95% CI: 1.04-1.09, p<0.001).
Table 2 shows echocardiographic parameters measured prior 
to TAVI. In the total cohort, mean left ventricular ejection frac-
tion (LVEF) was 53.9±14.4% and mean aortic valve area (AVA) 
was 0.7±0.2 cm2. In univariable analysis, LVEF (50.4±15.6% vs. 
Table 1. Baseline clinical characteristics.
Overall
n=469
Patients alive
at 2 years
n=351
Patients dead
at 2 years
n=118
Hazard ratio  
(95% CI)
p-value
Age (years) 82.3±5.5 82.2±5.5 82.7±5.4 1.01 (0.98-1.05) 0.41
Female gender, n (%) 264 (56%) 204 (58%) 60 (51%) 0.78 (0.54-1.12) 0.18
Height (cm) 164.7±8.2 164.6±8.1 164.9±8.6 1.00 (0.98-1.03) 0.74
Weight (kg) 71.3±15.2 71.6±14.6 70.2±16.7 0.99 (0.98-1.01) 0.29
Body mass index (kg/m2) 26.2±5.1 26.4±5.0 25.7±5.5 0.97 (0.94-1.01) 0.15
Body surface area (m2) 1.8±0.2 1.8±0.2 1.8±0.2 0.64 (0.28-1.47) 0.30
Diabetes mellitus, n (%) 133 (28%) 87 (25%) 46 (39%) 1.74 (1.20-2.52) 0.003
Hypercholesterolaemia, n (%) 306 (65%) 232 (66%) 74 (63%) 0.87 (0.60-1.26) 0.46
Hypertension, n (%) 397 (85%) 300 (85%) 97 (82%) 0.80 (0.50-1.29) 0.37
Current smoker, n (%) 39 (9%) 28 (9%) 11 (10%) 1.08 (0.58-2.01) 0.81
Coronary artery disease, n (%) 305 (65%) 221 (63%) 84 (71%) 1.36 (0.91-2.02) 0.13
Multivessel disease, n (%) 192 (41%) 135 (38%) 57 (48%) 1.39 (0.97-1.99) 0.074
Prior MI, n (%) 67 (14%) 41 (12%) 26 (22%) 1.83 (1.19-2.83) 0.006
Prior CABG, n (%) 37 (9%) 28 (9%) 9 (9%) 0.97 (0.49-1.92) 0.93
Prior PCI, n (%) 127 (27%) 92 (26%) 35 (30%) 1.16 (0.78-1.71) 0.48
Prior cerebrovascular accident, n (%) 52 (11%) 37 (11%) 15 (13%) 1.25 (0.73-2.15) 0.42
Peripheral artery disease, n (%) 96 (20%) 64 (18%) 32 (27%) 1.53 (1.02-2.29) 0.040
Chronic obstructive pulmonary disease, n (%) 79 (17%) 55 (16%) 24 (20%) 1.34 (0.86-2.10) 0.20
Renal failure (GFR <60 ml/min/1.73 m2) 326 (70%) 241 (69%) 85 (73%) 1.20 (0.80-1.80) 0.39
Atrial fibrillation 320 (68%) 248 (71%) 72 (61%) 1.46 (1.01-2.11) 0.045
Syncope, n (%) 66 (14%) 49 (14%) 17 (14%) 1.02 (0.61-1.70) 0.96
NYHA functional Class III/IV, n (%) 325 (69%) 238 (68%) 87 (74%) 1.28 (0.85-1.92) 0.24
CCS Class III/IV, n (%) 66 (14%) 50 (14%) 16 (14%) 0.95 (0.56-1.62) 0.86
Logistic EuroSCORE (%) 23.7±13.9 22.4±13.1 27.6±15.5 1.02 (1.01-1.03) <0.001
STS score (%) 6.9±4.5 6.4±4.1 8.4±5.4 1.06 (1.04-1.09) <0.001
Medication at admission
Aspirin, n (%) 297 (64%) 222 (64%) 75 (64%) 1.01 (0.69-1.47) 0.96
Clopidogrel, n (%) 91 (20%) 70 (20%) 21 (18%) 0.90 (0.56-1.44) 0.66
Oral anticoagulation, n (%) 126 (27%) 88 (25%) 38 (32%) 1.35 (0.92-1.99) 0.13
Diuretic, n (%) 334 (72%) 242 (69%) 92 (79%) 1.52 (0.98-2.37) 0.061
Beta-blocker, n (%) 247 (53%) 190 (54%) 57 (49%) 0.83 (0.58-1.19) 0.303
ACEi/ARB, n (%) 249 (53%) 188 (54%) 61 (52%) 0.93 (0.65-1.34) 0.71
Ca channel blocker, n (%) 79 (17%) 65 (19%) 14 (12%) 0.62 (0.35-1.08) 0.093
Statin, n (%) 231 (50%) 175 (50%) 56 (48%) 0.91 (0.63-1.31) 0.62
Data are expressed as mean±SD or number (%). Univariable hazard ratios (95% CIs) and p-values were derived from Cox regression models after 
multiple imputation of missing covariate data (combined estimate of 10 data sets using Rubin’s rule). ACE: angiotensin-converting enzyme; 
ARB: angiotensin receptor blockers; CABG: coronary artery bypass graft; CCS: Canadian Cardiovascular Society; MI: myocardial infarction; NYHA: New 
York Heart Association; PCI: percutaneous coronary intervention
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Right heart catheterisation and TAVI
55.1±13.8%, HR 0.83, 95% CI: 0.74-0.93, p=0.002), moderate 
or severe mitral regurgitation (38% vs. 21%, HR 2.04, 95% CI: 
1.41-2.96, p<0.001) and moderate or severe tricuspid regurgitation 
(29% vs. 16%, HR 1.94, 95% CI: 1.30-2.89, p<0.001) were asso-
ciated with an increased risk of death at two years.
HAEMODYNAMIC PARAMETERS AT PREOPERATIVE RHC
RHC-derived measures are reported in Table 3. Patients who 
had died within two years after intervention were more likely 
to have higher mean PAP (35.09±10.58 vs. 32.51±11.88 mmHg, 
HR 1.19, 95% CI: 1.02-1.38, p=0.029), lower pulmonary arte-
rial compliance (1.56±0.81 vs. 1.89±0.95 ml.mmHg–1, HR 0.65, 
95% CI: 0.51-0.84, p=0.001), higher transpulmonic gradient 
(14.22±10.41 vs. 10.95±11.44, HR 1.25, 95% CI: 1.07-1.47, 
p=0.006), higher pulmonary vascular resistance (359.84±308.99 
vs. 265.46±302.50 mmHg.min.L–1, HR 1.09, 95% CI: 1.03-1.15, 
p=0.003) and higher mean RAP (8.97±6.13 vs. 7.76±4.55 mmHg, 
HR 1.61, 95% CI: 1.13-2.31, p=0.009).
INDEPENDENT PREDICTORS OF DEATH AT TWO YEARS
Relevant variables among clinical, echocardiographic and haemo-
dynamic measures were entered in a multivariable Cox proportional 
analysis in a forward stepwise fashion (Table 4): diabetes (HR 
1.95, 95% CI: 1.28-2.96, p=0.001), transapical access (HR 1.66, 
95% CI: 1.07-2.56, p=0.02) and moderate or severe mitral regur-
gitation (HR 1.55, 95% CI: 1.00-2.39, p=0.04) at baseline were 
independently associated with all-cause mortality at two years.
Table 2. Baseline echocardiographic parameters.
Overall
n=469
Patients alive
at 2 years
n=351
Patients dead
at 2 years
n=118
Hazard ratio 
(95% CI)
p-value
Aortic valve area (cm2) 0.7±0.2 0.7±0.2 0.7±0.2 0.86 (0.37-1.98) 0.72
Indexed aortic valve area (cm2·m–2) 0.3±0.1 0.3±0.1 0.3±0.1 0.63 (0.06-6.25) 0.70
Aortic maximal velocity (cm/s) 4.1±0.8 4.1±0.8 4.0±0.9 0.87 (0.67-1.13) 0.30
Mean gradient (mmHg) 44.0±16.9 44.3±16.1 43.2±19.2 0.97 (0.87-1.09)* 0.60
Peak gradient (mmHg) 70.3±26.1 70.9±24.5 68.5±30.3 0.97 (0.90-1.05)* 0.43
LV end-diastolic diameter (mm) 49.2±8.8 48.8±8.9 50.1±8.3 1.14 (0.90-1.43)* 0.28
LV end-systolic diameter (mm) 33.6±10.4 33.1±10.4 35.1±10.3 1.16 (0.94-1.43)* 0.18
LV mass index (g/m2) 145.7±44.3 144.0±44.9 150.9±42.5 1.03 (0.98-1.08)* 0.20
LV ejection fraction (%) 53.9±14.4 55.1±13.8 50.4±15.6 0.83 (0.74-0.93)* 0.002
Stroke volume index (mL.m–2) 36.8±11.8 38.1±11.7 33.6±11.8 0.74 (0.58-0.95)* 0.019
TAPSE (mm) 18.0±5.1 18.2±4.8 17.7±5.8 0.98 (0.93-1.03) 0.43
DTI velocity (cm·sec–1) 11.5±3.1 11.3±3.0 11.9±3.2 1.04 (0.96-1.13) 0.31
Aortic regurgitation moderate or severe 36 (8%) 29 (9%) 7 (6%) 0.80 (0.37-1.71) 0.57
Mitral regurgitation moderate or severe 119 (25%) 74 (21%) 45 (38%) 2.04 (1.41-2.96) <0.001
Tricuspid regurgitation moderate or severe 89 (19%) 55 (16%) 34 (29%) 1.94 (1.30-2.89) 0.001
RV-RA gradient (mmHg) 39.2±12.5 37.4±12.3 44.8±11.2 1.04 (1.02-1.05) <0.001
Central venous pressure (mmHg) 8.9±3.8 8.5±3.7 10.2±3.8 1.10 (1.04-1.16) <0.001
Pulmonary artery systolic pressure (mmHg) 48.3±14.3 46.1±14.1 55.3±12.7 1.04 (1.02-1.05) <0.001
Data are expressed as mean±SD or number (%). Univariable hazard ratios (95% CIs) and p-values were derived from Cox regression models after 
multiple imputation of missing covariate data (combined estimate of 10 data sets using Rubin’s rule). * HR per ×10 units increase. DTI: Doppler tissue 
imaging; LV: left ventricle; RA: right atrium; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion
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Figure 1. RHC prior to TAVI does not increase the prognostic value 
of clinical and echocardiographic factors.
LACK OF INCREMENTAL UTILITY OF RHC TO PREDICT 
MORTALITY AFTER TAVI
Sequential models for the prediction of death were created to 
assess the incremental contribution of preoperative RHC rela-
tive to clinical and echocardiographic parameters. As shown in 
Figure 1, the Harrell’s C-statistic was 0.662 (95% CI: 0.612-
0.713) in a model including clinical and echocardiographic para-
meters and 0.667 (95% CI: 0.615-0.719) with implementation of 
RHC-derived metrics (p=0.47).
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Table 3. Measures at preoperative RHC.
Overall
n=469
Patients alive
at 2 years
n=351
Patients dead
at 2 years
n=118
Hazard ratio 
(95% CI)
p-value
Systolic arterial pressure (mmHg) 136±28.4 137.4±28.5 131.7±27.7 0.94 (0.88-1.00) 0.056
Diastolic arterial pressure (mmHg) 65.7±13.9 66.3±14.1 63.9±12.9 0.90 (0.79-1.03) 0.12
Mean arterial pressure (mmHg) 93.9±17.8 94.7±18.0 91.3±16.7 0.91 (0.82-1.01) 0.081
Systemic vascular resistance (dynes·cm–5) 1,964.1±670.1 1,954.5±648.1 1,993.1±734.9 1.01 (0.98-1.04) 0.55
Systemic arterial compliance (ml·mmHg–1) 0.44±0.20 0.43±0.18 0.45±0.24 1.62 (0.64-4.12) 0.31
Valvulo-arterial impedance (mmHg·ml·m2) 7.34±2.57 7.33±2.52 7.39±2.71 1.01 (0.94-1.09) 0.74
LV systolic pressure (mmHg) 188.2±34.7 190.6±33.1 180.8±38.4 0.93 (0.88-0.98) 0.011
LV end-diastolic pressure (mmHg) 21.4±8.0 21.5±8.1 20.1±7.7 0.93 (0.73-1.17) 0.51
LV development pressure (mmHg) 166.7±32.8 169.0±30.9 159.8±37.2 0.93 (0.87-0.98) 0.010
LV stroke work (g·m) 92.0±32.6 94.2±31.9 85.2±33.9 0.92 (0.86-0.98) 0.012
Stroke volume (ml) 49.5±15.7 50.2±15.6 47.2±15.9 0.89 (0.78-1.01) 0.061
Stroke volume index (ml/m2) 27.7±7.9 28.1±8.0 26.6±7.8 0.80 (0.63-1.02) 0.072
Cardiac output (L/min) 3.7±1.0 3.8± 0.9 3.6±1.1 0.84 (0.69-1.02) 0.072
Cardiac index (L/min/m2) 2.1±0.5 2.1± 0.5 2.0±0.5 0.71 (0.48-1.03) 0.074
PA systolic pressure (mmHg) 51.6±17.1 50.2±17.1 55.5±16.5 1.16 (1.05-1.28) 0.003
PA diastolic pressure (mmHg) 20.2±8.7 19.8±8.8 21.4±8.0 1.22 (0.99-1.50) 0.061
Mean PA pressure (mmHg) 33.2±11.6 32.5±11.9 35.1±10.6 1.19 (1.02-1.38) 0.029
Pulmonary arterial compliance (ml·mmHg–1) 1.8±0.9 1.9±0.9 1.5±0.8 0.65 (0.51-0.84) 0.001
Diastolic pulmonary gradient (mmHg) –1.1±9.0 –1.7±9.1 0.6±8.6 1.03 (1.01-1.05) 0.013
Transpulmonic gradient (mmHg) 11.7±11.2 10.9±11.4 14.2±10.4 1.25 (1.07-1.47) 0.006
Pulmonary vascular resistance (mmHg·min·L–1) 289.11±306.54 265.4±302.5 359.8±309 1.09 (1.03-1.15) 0.003
Pulmonary vascular resistance (Wood units) 3.6±3.9 3.3±3.8 4.5±3.9 1.07 (1.02-1.12) 0.003
RV systolic pressure (mmHg) 51±16.5 49.9±16.4 54.3±16.3 1.15 (1.04-1.27) 0.009
RV end-diastolic pressure (mmHg) 9.9±5.4 9.9±5.3 10.2±5.8 1.12 (0.80-1.58) 0.50
RA mean pressure (mmHg) 8.1±5.0 7.8±4.5 9±6.1 1.61 (1.13-2.31) 0.009
RV stroke work index (g·m·m–2·beat–1) 32.3±11.1 33.2±11.3 29.4±10.2 0.97 (0.95-0.99) 0.001
Aortic saturation (%) 94±3.6 94±3.6 94.1±3.6 1.07 (0.64-1.78) 0.80
Pulmonary artery saturation (%) 60.8±8.5 61.6±8.3 58.4±8.9 0.71 (0.58-0.85) <0.001
Data are expressed as mean±SD or number (%). Univariable hazard ratios (95% CIs) and p-values were derived from Cox regression models after 
multiple imputation of missing covariate data (combined estimate of 10 data sets using Rubin’s rule). LV: left ventricle; PA: pulmonary artery; RA: right 
atrium; RV: right ventricle
Table 4. Multivariable model.
Hazard ratio  
(95% CI)
p-value
Age (years) 1.04 (1.00-1.08) 0.082
Body mass index (kg/m2) 0.98 (0.94-1.02) 0.32
Diabetes mellitus 1.95 (1.28-2.96) 0.001
Previous cerebrovascular accident 1.30 (0.75-2.26) 0.36
Chronic obstructive pulmonary disease 1.41 (0.87-2.27) 0.17
Transapical access 1.66 (1.07-2.56) 0.02
STS risk score 1.02 (0.99-1.06) 0.16
Mitral regurgitation (moderate or severe) 1.55 (1.00-2.39) 0.047
Left ventricular ejection fraction 0.91 (0.79-1.05) 0.20
Mean aortic valve gradient 1.05 (0.92-1.18) 0.49
Pulmonary arterial compliance  
(ml·mmHg–1) 0.73 (0.47-1.13) 0.16
RA mean pressure (mmHg) 1.13 (0.75-1.69) 0.56
Multivariable model after multiple imputation of missing values, 
estimates from combining 20 imputed data sets. RA: right atrium
ROLE OF RHC AMONG PATIENTS WITH PULMONARY 
HYPERTENSION AT BASELINE
Among patients with baseline pulmonary hypertension, defined as 
mean PAP ≥25 mmHg, clinical and echocardiographic variables 
(age: HR 1.06, 95% CI: 1.01-1.12, p=0.03; diabetes: HR 2.46, 
95% CI: 1.52-3.96, p<0.001; moderate or severe mitral regurgi-
tation: HR 1.67, 95% CI: 1.03-2.70, p=0.03), but not haemody-
namic indices, were predictors of two-year mortality. The addition 
of haemodynamic variables did not significantly increase the 
prognostic value of a model including clinical and echocardio-
graphic parameters (Figure 2).
Discussion
In the present study, RHC-derived measures failed to predict mor-
tality among patients undergoing TAVI; furthermore, the addition 
of haemodynamic parameters did not significantly improve the 
prognostic power of a model containing clinical and echocardio-
graphic variables. Intracardiac haemodynamics featuring patients 
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Figure 2. RHC prior to TAVI does not increase the prognostic value 
of clinical and echocardiographic factors among patients with 
pulmonary hypertension at baseline.
with severe AS have been previously assessed9. The haemody-
namic parameter with the highest prognostic value in the setting 
of severe AS is undoubtedly pulmonary hypertension. It oper-
ates the continuum between left ventricular dysfunction and right 
heart failure in the context of pressure overload: indeed, the back-
ward transmission of the elevated pressures in the hypertrophic 
left ventricle promotes the remodelling of pulmonary vasculature. 
The presence of pulmonary hypertension affects the prognosis of 
patients with severe AS irrespective of the treatment7,10,11. In this 
context, we sought to investigate whether other invasive haemo-
dynamic parameters, among those mirroring the pathophysiology 
of the valvular disease, could be related to mortality after TAVI.
The prognostic significance of several RHC-derived measures 
has been assessed in other clinical settings. Specifically, elevated 
mean right atrial pressure and lower cardiac index independently 
predict mortality among patients with pulmonary arterial hyper-
tension (group I)1. A reduced pulmonary arterial compliance 
proved a powerful marker of poor prognosis in decompensated 
heart failure12. Nevertheless, in our study, none of the haemody-
namic parameters obtained at RHC prior to TAVI proved to have 
better capability to predict mortality than clinical factors. Among 
these, diabetes is quoted within the scores commonly used to 
estimate the operative risk of patients. Analyses of registry data 
showed that insulin-treated subjects and those with poorer gly-
caemic control (as indicated by higher values of glycated hae-
moglobin A1c) were at increased risk for mortality at long-term 
follow-up13,14. Indeed, diabetic status is supposed to impair the 
left ventricular reverse remodelling and regression of hypertrophy 
triggered by the relief of valvular stenosis15. Similarly, the inde-
pendent association between moderate or severe mitral regurgita-
tion at baseline and the risk of death after TAVI has been widely 
documented16-18. In addition, the survival advantage of transfemo-
ral compared with transapical TAVI is also in line with previous 
findings. A significant survival benefit in the subgroup of patients 
allocated to transfemoral TAVI compared with surgical interven-
tion has been reported in a recent meta-analysis of randomised 
trials including patients at high risk and lower-than-high risk19. 
Patient- and procedure-related factors contribute to enhance the 
risk of worse outcomes among subjects undergoing transapical 
TAVI. The patients are typically older and have more cardiovas-
cular risk factors. In addition, access-related myocardial damage 
can affect the recovery of left ventricular function and provide the 
substrate for arrhythmic events.
In our study, the superior prognostic value of clinical over 
haemodynamic factors was confirmed in the subgroup of patients 
with pulmonary hypertension at baseline.
Similarly, in a sub-analysis of the PARTNER-I trial, including 
patients with preoperative moderate or severe pulmonary hyper-
tension, clinical factors such as oxygen-dependent lung disease, 
inability to perform a six-minute walk test, impaired renal func-
tion and lower aortic valve mean gradient proved more inform-
ative about survival at one year compared with RHC-derived 
measures20. Yet, while haemodynamic variables, such as the mean 
right atrial pressure, proved to have independent prognostic abil-
ity in patients with pulmonary arterial hypertension (group I), they 
failed to predict mortality in subjects with pulmonary hyperten-
sion secondary to left heart diseases (group II)21 .
Overall, our results suggest that clinical factors affect long-term out-
comes after TAVI to a greater extent than haemodynamic parameters. 
In this regard, clinical characteristics and comorbidities at baseline 
represent the variables with greatest prognostic weight in recently 
developed scores to predict early and late mortality after TAVI22.
Previous investigations by our group focused on the effect of 
haemodynamic patterns of pulmonary hypertension or low-flow, 
low-gradient aortic stenosis on clinical outcomes after TAVI7,23. 
Instead, the present analysis sought to determine whether preoper-
ative RHC provides additional prognostic value on top of standard, 
non-invasive evaluation including clinical and echocardiographic 
parameters. Although several haemodynamic parameters were 
associated with two-year mortality at univariable analysis, there 
was a lack of incremental prognostic information provided by 
RHC when clinical and echocardiographic parameters were con-
sidered. The present study, therefore, provides a nuanced apprecia-
tion of the role of invasive haemodynamic measurements before 
TAVI and suggests that RHC could be a dispensable tool for prog-
nostication in the preoperative diagnostic workup if comprehen-
sive non-invasive information is already available.
Limitations
We acknowledge the following limitations of our analysis: 1) the 
retrospective design of the study conveys intrinsic biases such as 
the unrecognised presence of confounding factors with impact on 
mortality after TAVI; 2) referral bias can be present as patients 
received RHC prior to TAVI on the basis of their clinical history; 
in particular, haemodynamically unstable patients may have been 
referred to TAVI without previous RHC; 3) we did not assess 
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whether changes in haemodynamic intracardiac profile occurred 
after TAVI and whether they had an impact on long-term mortal-
ity; 4) as the study cohort comprised elderly and high-risk patients, 
the results could not apply to younger and lower-risk subjects; 
5) while complications resulting from preoperative left and right 
heart catheterisation were generally rare and limited to access-site 
complications, adverse events attributable to RHC were not sys-
tematically collected in the setting of our study.
Conclusions
The invasive assessment of haemodynamic parameters provides 
important information on the pathophysiology of aortic stenosis, 
patient prognosis, and functional status after valve replacement. 
Nevertheless, in an era witnessing a progressive streamlining of 
TAVI procedures, routine RHC may become a dispensable tool for 
prognosis assessment when comprehensive data from non-inva-
sive diagnostics are available.
Impact on daily practice
This study suggests that clinical baseline characteristics have 
a greater prognostic impact than haemodynamic indices in 
patients evaluated for transcatheter aortic valve implantation 
(TAVI).
Conflict of interest statement
S. Windecker reports having received research grants to the 
institution from Abbott, Biotronik, Boston Scientific, Edwards 
Lifesciences, Medtronic, The Medicines Company, and St. Jude as 
well as speaker fees from AstraZeneca, Eli Lilly, Abbott, Biotronik, 
Boston Scientific, Bayer, and Biosensors. L. Räber has received 
speaker fees and research grants to the institution from St. Jude 
Medical. The other authors have no conflicts of interest to declare.
References
 1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, 
Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, 
Liou TG, McGoon MD. Predicting survival in pulmonary arterial 
hypertension: insights from the Registry to Evaluate Early and 
Long-Term Pulmonary Arterial Hypertension Disease Management 
(REVEAL). Circulation. 2010;122:164-72.
 2. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, 
Bonapace S, Dini FL, Temporelli PL, Vassanelli C, Vanderpool R, 
Naeije R, Ghio S. Prognostic relevance of pulmonary arterial compli-
ance in patients with chronic heart failure. Chest. 2014;145:1064-70.
 3. Pibarot P, Dumesnil JG. New concepts in valvular hemody-
namics: implications for diagnosis and treatment of aortic stenosis. 
Can J Cardiol. 2007;23 Suppl B:40B-47B.
 4. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in 
aortic valve stenosis: preventive or promotive of systolic dysfunc-
tion and heart failure? Eur Heart J. 2005;26:1790-6.
 5. Lucon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, 
Eltchaninoff H, Iung B, Leguerrier A, Laskar M, Leprince P, 
Gilard M, Le Breton H. Prognostic implications of pulmonary 
hypertension in patients with severe aortic stenosis undergoing 
transcatheter aortic valve implantation: study from the FRANCE 2 
Registry. Circ Cardiovasc Interv. 2014;7:240-7.
 6. Ben-Dor I, Goldstein SA, Pichard AD, Satler LF, Maluenda G, 
Li Y, Syed AI, Gonzalez MA, Gaglia MA Jr, Wakabayashi K, 
Delhaye C, Belle L, Wang Z, Collins SD, Torguson R, Okubagzi P, 
Aderotoye A, Xue Z, Suddath WO, Kent KM, Epstein SE, Lindsay J, 
Waksman R. Clinical profile, prognostic implication, and response 
to treatment of pulmonary hypertension in patients with severe aor-
tic stenosis. Am J Cardiol. 2011;107:1046-51.
 7. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, 
Stortecky S, Heg D, Spitzer E, Zanchin T, Praz F, Tuller D, Huber C, 
Pilgrim T, Nietlispach F, Khattab AA, Carrel T, Meier B, 
Windecker S, Buellesfeld L. Effect of Pulmonary Hypertension 
Hemodynamic Presentation on Clinical Outcomes in Patients With 
Severe Symptomatic Aortic Valve Stenosis Undergoing 
Transcatheter Aortic Valve Implantation: Insights From the New 
Proposed Pulmonary Hypertension Classification. Circ Cardiovasc 
Interv. 2015;8:e002358.
 8. Wenaweser P, Pilgrim T, Kadner A, Huber C, Stortecky S, 
Buellesfeld L, Khattab AA, Meuli F, Roth N, Eberle B, Erdos G, 
Brinks H, Kalesan B, Meier B, Jüni P, Carrel T, Windecker S. 
Clinical outcomes of patients with severe aortic stenosis at increased 
surgical risk according to treatment modality. J Am Coll Cardiol. 
2011;58:2151-62.
 9. Chang SA, Park PW, Sung K, Lee SC, Park SW, Lee YT, 
Oh JK. Noninvasive estimate of left ventricular filling pressure cor-
related with early and midterm postoperative cardiovascular events 
after isolated aortic valve replacement in patients with severe aortic 
stenosis. J Thorac Cardiovasc Surg. 2010;140:1361-6.
 10. Zlotnick DM, Ouellette ML, Malenka DJ, DeSimone JP, 
Leavitt BJ, Helm RE, Olmstead EM, Costa SP, DiScipio AW, 
Likosky DS, Schmoker JD, Quinn RD, Sisto D, Klemperer JD, 
Sardella GL, Baribeau YR, Frumiento C, Brown JR, O’Rourke DJ; 
Northern New England Cardiovascular Disease Study Group. 
Effect of preoperative pulmonary hypertension on outcomes in 
patients with severe aortic stenosis following surgical aortic valve 
replacement. Am J Cardiol. 2013;112:1635-40.
 11. Pilgrim T, Englberger L, Rothenbühler M, Stortecky S, 
Ceylan O, O’Sullivan CJ, Huber C, Praz F, Buellesfeld L, 
Langhammer B, Meier B, Jüni P, Carrel T, Windecker S, Wenaweser P. 
Long-term outcome of elderly patients with severe aortic stenosis as 
a function of treatment modality. Heart. 2015;101:30-6.
 12. Miller WL, Grill DE, Borlaug BA. Clinical features, hemody-
namics, and outcomes of pulmonary hypertension due to chronic 
heart failure with reduced ejection fraction: pulmonary hyperten-
sion and heart failure. JACC Heart Fail. 2013;1:290-9.
 13. Abramowitz Y, Jilaihawi H, Chakravarty T,  Mangat G, 
Maeno Y, Kazuno Y, Takahashi N, Kawamori H, Cheng W, 
Makkar RR. Impact of Diabetes Mellitus on Outcomes After Trans-
catheter Aortic Valve Implantation. Am J Cardiol. 2016;117: 
1636-42.
e2193
EuroIntervention 2
0
17;1
2
:e
218
6
-e
219
3
Right heart catheterisation and TAVI
 14. Chorin E, Finkelstein A, Banai S, Aviram G, Barkagan M, 
Barak L, Keren G, Steinvil A. Impact of Diabetes Mellitus and 
Hemoglobin A1C on Outcome After Transcatheter Aortic Valve 
Implantation. Am J Cardiol. 2015;116:1898-903.
 15. Nakamura T, Toda K, Kuratani T, Miyagawa S, Yoshikawa Y, 
Fukushima S, Saito S, Yoshioka D, Kashiyama N, Daimon T, 
Sawa Y. Diabetes Mellitus Impairs Left Ventricular Mass Regression 
after Surgical or Transcatheter Aortic Valve Replacement for Severe 
Aortic Stenosis. Heart Lung Circ. 2016;25:68-74.
 16. Takagi H, Umemoto T; All-Literature Investigation of 
Cardiovascular Evidence Group. Coexisting Mitral Regurgitation 
Impairs Survival After Transcatheter Aortic Valve Implantation. 
Ann Thorac Surg. 2015;100:2270-6.
 17. Khawaja MZ, Williams R, Hung J, Arri S, Asrress KN, 
Bolter K, Wilson K, Young CP, Bapat V, Hancock J, Thomas M, 
Redwood S. Impact of preprocedural mitral regurgitation upon 
mortality after transcatheter aortic valve implantation (TAVI) for 
severe aortic stenosis. Heart. 2014;100:1799-803.
 18. Sannino A, Losi MA, Schiattarella GG, Gargiulo G, Perrino C, 
Stabile E, Toscano E, Giugliano G, Brevetti L, Franzone A, Cirillo P, 
Imbriaco M, Trimarco B, Esposito G. Meta-analysis of mortality 
outcomes and mitral regurgitation evolution in 4,839 patients hav-
ing transcatheter aortic valve implantation for severe aortic steno-
sis. Am J Cardiol. 2014;114:875-82.
 19. Siontis GC, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, 
Sondergaard L, Jüni P, Windecker S. Transcatheter aortic valve 
implantation vs. surgical aortic valve replacement for treatment of 
severe aortic stenosis: a meta-analysis of randomized trials. Eur 
Heart J. 2016;37:3503-3512.
 20. Lindman BR, Zajarias A, Maniar HS, Miller DC, Suri RM, 
Arnold SV, Webb J, Svensson LG, Kodali S, Xu K, Ayele GM, 
Lin F, Wong SC, Babaliaros V, Thourani VH, Douglas PS, Lim S, 
Leon MB, Mack MJ. Risk stratification in patients with pulmonary 
hypertension undergoing transcatheter aortic valve replacement. 
Heart. 2015;101:1656-64.
 21. Yamabe S, Dohi Y, Fujisaki S, Higashi A, Kinoshita H, 
Sada Y, Hidaka T, Kurisu S, Yamamoto H, Kihara Y. Prognostic 
Factors for Survival in Pulmonary Hypertension Due to Left Heart 
Disease. Circ J. 2016;80:243-9.
 22. Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack M, 
Shanian D, Grover FL, Tuzcu EM, Thourani VH, Carrol J, 
Brennan M, Brindis R, Rumsfeld J, Holmes DR Jr; Steering 
Committee of the Society of Thoracic Surgeons/American College 
of Cardiology Transcatheter Valve Therapy Registry. Development 
and Validation of a Risk Prediction Model for In-Hospital Mortality 
After Transcatheter Aortic Valve Replacement. JAMA Cardiol. 
2016;1:46-52.
 23. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, 
Buellesfeld L, Khattab AA, Nietlispach F, Moschovitis A, 
Zanchin T, Meier B, Windecker S, Wenaweser P. Clinical out-
comes of patients with low-flow, low-gradient, severe aortic ste-
nosis and either preserved or reduced ejection fraction undergoing 
transcatheter aortic valve implantation. Eur Heart J. 2013;34: 
3437-50.
